Merck KGaA cut its mid-term sales growth target for its health-care division after a number of high-profile drug trial ...

(Reuters) -German science and technology group Merck is open to more acquisitions for its Life Science business after ...

German science and technology giant Merck on Thursday said it is confident of returning to medium-term growth after a ...

Merck (NYSE: MRK) is a top pharmaceutical company coming off a good quarter that shows it is growing its top and bottom lines. Even with that growth, the stock still trades at a fairly modest ...

Merck's recent decline is due to reduced profit guidance and FDA decisions, but shares are at a support level that is likely to hold. Keytruda remains a key revenue driver, with potential for ...

Sept 25 (Reuters) - Merck (MRK.N), opens new tab said on Wednesday a combination of its experimental drug and blockbuster therapy Keytruda failed a late-stage trial testing it in previously ...

Merck & Co. has picked up options on two Evaxion Biotech vaccine candidates, paying $3.2 million and dangling more than $1 billion in milestones for the chance to pick up preclinical prospects ...

A Merck & Co. Inc. diverse leadership program unlawfully excludes White and Asian workers, according to an EEOC charge filed ...

EXEL is set to evaluate investigational zanzalintinib in combination with Merck;s Keytruda (pembrolizumab) and Welireg in head and neck cancer and renal cell carcinoma, respectively. ALAMEDA ...

Looking at a slightly longer term, the performance of PFE stock with respect to the index has been quite volatile in recent ...

During an R&D update yesterday Merck said it is hoping to claim eight new cardiovascular therapy approvals between now and 2030, for diseases like atherosclerosis, heart failure, pulmonary ...

Jefferies analyst Brian Balchin maintained a Buy rating on Merck KGaA (0O14 – Research Report) today and set a price target of €180.00.